natgillin/translations-raw huggingface dataset:
Blood pressure may also be lowered by one of the following drugs/ class of drugs: tricyclic antidepressants, antipsychotics, baclofene, amifostine. 
Krvni tlak vam lahko zniža tudi katero od naslednjih zdravil/skupin zdravil: triciklični antidepresivi, antipsihotiki, baklofen, amifostin.
In the treatment of heart failure, losartan is usually combined with a diuretic (medicine that increases the amount of water that you pass out through your kidneys) and/or digitalis (medicine that helps to make the heart stronger and more efficient) and/or a beta-blocker. 
Pri zdravljenju srčnega popuščanje se losartan običajno kombinira z diuretikom (zdravilo, ki poveča količino vode, ki se izloči skozi ledvice) in/ali digitalisom (zdravilo, ki pripomore, da je srce močnejše in učinkovitejše) in/ali beta zaviralcem.
Renal function should be regularly monitored during treatment with losartan as it may deteriorate. 
Med zdravljenjem z losartanom je treba redno kontrolirati delovanje ledvic, ker se lahko poslabša.
COZAAR powder and solvent for oral suspension is packaged in a kit containing: 
COZAAR prašek in vehikel za peroralno suspenzijo je pakiran tako, da vsebuje:
What COZAAR is and what it is used for Before you take COZAAR How to take COZAAR Possible side effects How to store COZAAR Further information 
Kaj je zdravilo COZAAR in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo COZAAR Kako jemati zdravilo COZAAR Možni neželeni učinki
PHARMACEUTICAL FORM AND CONTENTS 473 ml solvent 
FARMACEVTSKA OBLIKA IN VSEBINA 473 ml vehikla
It is normal to have a small amount of residual powder adhering to the interior surfaces of the sachet. 
Normalno je, da nekaj praška ostane na notranjih površinah vrečke.
• 2nd and 3rd trimester of pregnancy (see section 4.6). 
• Drugo in tretje trimesečje nosečnosti (glejte poglavje 4.6).
Compared to patients with normal renal function, the AUC for Losartan is about 2times higher in haemodialysis dialysis patients. 
V primerjavi z bolniki z normalno ledvično funkcijo je pri bolnikih na hemodializi AUC losartana približno 2-krat večja.
Data in the pediatric population are limited. 
Podatkov za pediatrične bolnike je malo.
These results were confirmed during period II of the study where patients were randomized to continue losartan or placebo, after three weeks of treatment. 
Ti rezultati so bili potrjeni po treh tednih v drugem obdobju študije, v kateri so bolnike randomizirali tako, da so nadaljevali zdravljenje z losartanom ali pa prejemali placebo.
This pack contains: 
Pakiranje vsebuje:
• Lactation (see section 4.6). 
• Dojenje (glejte poglavje 4.6).
In these clinical trials, the most common adverse event was dizziness. 
V teh kliničnih preskušanjih je bil najpogostejši neželeni učinek omotica.
When pregnancy is diagnosed, treatment with losartan should be stopped immediately and, if appropriate, alternative therapy should be started. 
Ob potrjeni nosečnosti je treba zdravljenje z losartanom takoj prekiniti in, če je primerno, začeti alternativno zdravljenje.
Do not use COZAAR after the expiry date which is stated on the carton after EXP. 
Zdravila COZAAR ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake "Uporabno do".
What COZAAR looks like and contents of the pack 
Izgled zdravila COZAAR in vsebina pakiranja
12.5 mg and 50 mg (initiation pack) 
12.5 mg and 50 mg (začetno pakiranje)
• if you suffer from primary hyperaldosteronism (a syndrome associated with increased secretion of the hormone aldosterone by the adrenal gland, caused by an abnormality within the gland). 
• če imate primarni hiperaldosteronizem (sindrom povezan s povečanim izločanjem hormona aldosterona iz nadledvične žleze zaradi okvare znotraj železe).
If you forget to take COZAAR 
Če ste pozabili vzeti zdravilo COZAAR
• Reduction in the risk of stroke in adult hypertensive patients with left-ventricular hypertrophy documented by ECG (see section 5.1 LIFE study, Race). 
• Zmanjšanje tveganja za možgansko kap pri odraslih hipertenzivnih bolnikih s hipertrofijo levega prekata, potrjeno z EKG-jem (glejte poglavje 5.1 Študija LIFE, Rasa).
Adult Patients with Heart Failure 
Odrasli bolniki s srčnim popuščanjem
[See Annex I - To be completed nationally] {Name and address} <{tel}> <{fax}> <{e-mail}> 
[Glejte Dodatek I - Izpolni država članica] {Ime in naslov} <{tel}> <{fax}> <{e-naslov}>
An increased mortality was observed in ELITE II in the small subgroup (22 % of all HF patients) taking beta-blockers at baseline. 
Povečano smrtnost so opazili v majhni podskupini bolnikov iz študije ELITE II (22 % vseh bolnikov s srčnim popuščanjem), ki so na začetku jemali beta zaviralce.
When losartan is administered orally, about 4 % of the dose is excreted unchanged in the urine, and about 6 % of the dose is excreted in the urine as active metabolite. 
Po peroralnem odmerku losartana se približno 4 % zaužitega odmerka izloči v urin nespremenjenega, približno 6 % zaužitega odmerka pa v obliki aktivnega presnovka.
Remove the syringe and take the medicine. 
Odstranite brizgo in vzemite zdravilo.
• Treatment of chronic heart failure (in patients ≥ 60 years), when treatment with Angiotensinconverting enzyme (ACE) inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication. 
• Zdravljenje kroničnega srčnega popuščanja (pri bolnikih ≥ 60 let) kadar zdravljenje z zaviralci angiotenzinske konvertaze (ACE) ni primerno zaradi inkompatibilnosti, posebno kašlja, ali kontraindikacije.
Do not take: 
Ne jemljite zdravila:
A medical or healthcare professional/pharmacist mixes each sachet with 200 ml of solvent to create a suspension. 
Zdravstveno osebje/farmacevt zmeša eno vrečko praška z 200 ml vehikla, da nastane suspenzija.
In patients with heart failure, with or without renal impairment, there is - as with other medicinal products acting on the renin-angiotensin system - a risk of severe arterial hypotension, and (often acute) renal impairment. 
Pri bolnikih s srčnim popuščanjem z okvaro ledvic ali brez obstaja, tako kot pri drugih zdravilih, ki delujejo na sistem renin-angiotenzin, tveganje za hudo arterijsko hipotenzijo in (pogosto akutno) ledvično okvaro.
In a clinical trial it was found that fluconazole (inhibitor of CYP2C9) decreases the exposure to the active metabolite by approximately 50 %. 
V kliničnem preskušanju so ugotovili, da flukonazol (zaviralec CYP2C9) zmanjšuje izpostavljenost aktivnemu presnovku za približno 50 %.
Kit: Do not store above 25°C. 
Škatla z zdravilom in opremo: Ne shranjujte pri temperaturi nad 25 ºC.
Take particular care if you are taking the following medicines while under treatment with COZAAR: 
Še posebej pozorni bodite, če med zdravljenjem z zdravilom COZAAR jemljete katero od naslednjih zdravil:
Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. 
Sočasna uporaba antagonistov angiotenzina II ali diuretikov in NSAID-ov lahko poveča tveganje za poslabšanje ledvične funkcije, vključno z možno akutno ledvično odpovedjo, ter poveča količino kalija v serumu, še posebej pri bolnikih z že obstoječim slabim delovanjem ledvic.
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. 
Bolniki s primarnim hiperladosteronizmom se na zdravljenje z antihipertenzivi, ki zavirajo sistem renin-angiotenzin, večinoma ne odzovejo.
For the following individual and combined components of the primary endpoint, the results showed a significant risk reduction in the group treated with Losartan: 25.3 % risk reduction for doubling of the serum creatinine (p = 0.006); 28.6 % risk reduction for end-stage renal failure (p = 0.002); 19.9 % risk reduction for end-stage renal failure or death (p = 0.009); 21.0 % risk reduction for doubling of serum creatinine or end-stage renal failure (p = 0.01). 
V skupini, ki se je zdravila z losartanom, se je pomembno zmanjšalo tveganje za naslednje posamezne komponente primarnega opazovanega dogodka in njihove kombinacije: 25,3 % zmanjšanje tveganja za podvojitev kreatinina v serumu (p = 0,006); 28,6 % zmanjšanje tveganja za končno ledvično odpoved (p = 0,002), 19,9 % zmanjšanje tveganja za končno ledvično odpoved ali smrt (p = 0,009), 21,0 % zmanjšanje tveganja za podvojitev kreatinina v serumu ali končno ledvično odpoved (p = 0,01).
• Treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus with proteinuria ≥ 0.5 g/day as part of an antihypertensive treatment. 
• Zdravljenje bolezni ledvic pri odraslih bolnikih s hipertenzijo in sladkorno boleznijo tipa 2 s proteinurijo ≥ 0,5 g/dan kot del antihipertenzivnega zdravljenja.
Co-administration of lithium and losartan should be undertaken with caution. 
Pri sočasni uporabi litija in losartana je potrebna previdnost.
• very rapid and irregular heartbeat (atrial fibrillation) brain attack (stroke), 
• zelo hitro in neredno bitje srca (atrijska fibrilacija), možganska kap
Both losartan and its active metabolite are ≥99 % bound to plasma proteins, primarily albumin. 
Tako losartan kot njegov aktivni presnovek sta v ≥ 99 % vezana na plazemske proteine, predvsem na albumin.
Immune system disorders: rare: hypersensitivity: anaphylactic reactions, angiooedema including swelling of the larynx and glottis causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue; in some of these patients angiooedema had been reported in the past in connection with the administration of other medicines, including ACE inhibitors; vasculitis, including Henoch-Schönlein purpura. 
Bolezni imunskega sistema: redke: preobčutljivost: anafilaktične reakcije, angioedem vključno z otekanjem grla in glotisa, zaradi česar se zožijo dihalne poti, in/ali otekanjem obraza, ustnic, žrela in/ali jezika - pri nekaterih od teh bolnikov so v preteklosti poročali o angioedemu v povezavi z jemanjem drugih zdravil, vključno z zaviralci ACE; vaskulitis vključno s Henoch-Schönleinovo purpuro.
Always shake <COZAAR>oral suspension well before use! 
Pred uporabo suspenzijo COZAAR vedno dobro pretresite!
• non-steroidal anti-inflammatory drugs such as indomethacin, including cox-2-inhibitors (medicines that reduce inflammation, and can be used to help relieve pain), as they may reduce the blood lowering effect of losartan. 
• nesteroidna protivnetna zdravila, kot je indometacin, vključno z zaviralci COX-2 (zdravila, ki zdravijo vnetje in se lahko uporabljajo za odpravljanje bolečine), ker lahko zmanjšajo losartanov učinek znižanja krvnega tlaka.
Based on pharmacokinetic data which demonstrate significantly increased plasma concentrations of losartan in cirrhotic patients, a lower dose should be considered for patients with a history of hepatic impairment. 
Glede na farmakokinetične podatke, ki kažejo pomembno zvišanje plazemskih koncentracij losartana pri bolnikih s cirozo, je treba pri bolnikih, ki so kdaj imeli okvaro jeter, razmisliti o manjšem odmerku.
• if you receive diuretics (medicines that increase the amount of water that you pass out through your kidneys) or are under dietary salt restriction leading to an extreme loss of fluid and salt in your body (see section 3 ‘Dosage in special patient groups'), 
• če jemljete diuretike (zdravila, ki povečajo izločanje vode skozi ledvice) ali ste na dieti s hrano z zmanjšano količino soli, zaradi česar iz telesa izgubljate večje količine tekočine in soli (glejte poglavje 3 "Odmerjanje pri posebnih skupinah bolnikov").
Taking with food and drink COZAAR may be taken with or without food. 
Jemanje zdravila skupaj s hrano in pijačo Zdravilo COZAAR lahko vzamete s hrano ali na tešče.
About 14 % of an intravenously- or orally-administered dose of losartan is converted to its active metabolite. 
Približno 14 % intravenskega ali peroralnega odmerka losartana se pretvori v njegov aktivni presnovek.
• to treat patients with high blood pressure (hypertension) in adults and in children and adolescents 6 - 16 years of age. 
• za zdravljenje bolnikov z visokim krvnim tlakom (hipertenzijo) pri odraslih ter pri otrocih in mladostnikih, starih 6-16 let.
Reduction in the risk of stroke in hypertensive patients with left-ventricular hypertrophy documented by ECG 
Zmanjšanje tveganja za možgansko kap pri hipertenzivnih bolnikih s hipertrofijo levega prekata, potrjeno z EKG-jem
When angiotensin II antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid at anti-inflammatory doses and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. 
Če se antagonisti angiotenzina II uporabljajo sočasno z nesteroidnimi protivnetnimi učinkovinami (NSAID) (npr. selektivnimi zaviralci COX-2, acetilsalicilno kislino v protivnetnih odmerkih in neselektivnimi NSAID-i), se lahko antihipertenzivni učinek zmanjša.
Merck Sharp Dohme Chibret 3 av. Hoche 
Francija Merck Sharp Dohme Chibret 3 av. Hoche
• in patients with high blood pressure and a thickening of the left ventricle, COZAAR has been shown to decrease the risk of stroke (“LIFE indication”). 
• pri bolnikih z visokim krvnim tlakom in zadebeljenim levim prekatom zdravilo COZAAR zmanjša tveganje za možgansko kap ("indikacija iz študije LIFE").
Therefore the results observed with losartan in comparison with atenolol in the LIFE study with regard to cardiovascular morbidity/mortality do not apply for black patients with hypertension and left-ventricular hypertrophy. 
Zato rezultati glede srčno-žilne obolevnosti/smrtnosti iz študije LIFE za losartan v primerjavi z atenololom ne veljajo za bolnike črne rase s hipertenzijo in hipertrofijo levega prekata.
• Treatment of essential hypertension in adults and in children and adolescents 6 - 16 years of age. 
• Zdravljenje esencialne hipertenzije pri odraslih ter otrocih in mladostnikih, starih 6 - 16 let.
Store the prepared suspension in a refrigerator at 2-8°C. 
Pripravljeno suspenzijo shranjujte v hladilniku pri 2-8 ºC.
After reconstitution, store the liquid suspension in a refrigerator (at 2°C - 8°C) for up to 4 weeks. 
Po pripravi tekočo suspenzijo shranjujte v hladilniku (pri 2 ºC do 8 ºC) do 4 tedne.
Concomitant use with other substances which may induce hypotension as an adverse reaction (like tricyclic antidepressants, antipsychotics, baclofen, and amifostine) may increase the risk of hypotension. 
Sočasna uporaba z drugimi učinkovinami, ki imajo za neželeni učinek lahko hipotenzijo (kot triciklični antidepresivi, antipsihotiki, baklofen in amifostin) lahko poveča tveganje za hipotenzijo.
Cardiac disorders: rare: syncope, atrial fibrillation, cerebrovascular accident 
Srčne bolezni: redke: sinkopa, atrijska fibrilacija, možganskožilni dogodek
Losartan slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes. 
Losartan upočasni pešanje ledvic pri bolnikih z visokim krvnim tlakom in sladkorno boleznijo tipa 2.
PHARMACEUTICAL FORM AND CONTENTS 200 ml oral suspension 
FARMACEVTSKA OBLIKA IN VSEBINA 200 ml peroralne raztopine
The recommended starting dose in patients >20 to <50 kg is 0.7 mg/kg once daily (up to 25 mg total, in exceptional cases where target doses above 25 mg are required, the maximal dose is 50 mg). 
Priporočeni začetni odmerek pri bolnikih > 20 do < 50 kg je 0,7 mg/kg enkrat na dan (do skupno 25 mg, v izjemnih primerih, ko so potrebni odmerki nad 25 mg, je največji odmerek 50 mg).
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: Angiotensin II antagonists, plain, ATC code: C09CA01 5.1 Pharmacodynamic properties 
Farmakoterapevtska skupina: antagonisti angiotenzina II, enokomponentna zdravila, oznaka ATC: C09CA01
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <{DD month YYYY}> [To be completed nationally] 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET {DD/MM/LLLL} [Izpolni država članica]
Hypertension and type 2 diabetes with renal disease In a controlled clinical trial in 1513 type 2 diabetic patients 31 years of age and older with proteinuria (RENAAL study, see section 5.1) the most common drug-related adverse reactions which were reported for losartan are as follows: 
Hipertenzija in sladkorna bolezen tipa 2 z boleznijo ledvic V kontroliranem kliničnem preskušanju pri 1513 bolnikih, starih 31 let in več, s sladkorno boleznijo tipa 2 in proteinurijo (študija RENAAL, glejte poglavje 5.1) so najpogostejši z zdravilom povezani neželeni učinki, o katerih so poročali za losartan, sledeči:
The solvent is a cloudy, colorless liquid. 
Vehikel je motna, brezbarvna tekočina.
The dose-response relationship became very obvious in the low dose group compared to the middle dose group (period I: -6.2 mmHg vs. -11.65 mmHg), but was attenuated when comparing the middle dose group with the high dose group (period I: -11.65 mmHg vs. -12.21 mmHg). 
Razlika v odzivu na odmerek med skupinama z majhnim in srednjim odmerkom je bila zelo očitna (obdobje I: -6,2 mmHg proti -11,65 mmHg), in je bila med skupinama s srednjim in velikim odmerkom (obdobje I: -11,65 mmHg proti -12,21 mmHg) manjša.
The side effects of medicines are classified as follows: 
Neželeni učinki so razvrščeni kot je navedeno:
PHARMACEUTICAL FORM Powder and solvent for oral suspension. 
FARMACEVTSKA OBLIKA Prašek in vehikel za peroralno suspenzijo.
Shake the closed bottle of losartan oral suspension well before use. 
Zaprto plastenko peroralne suspenzije losartana pred uporabo dobro pretresite.
- In some patients the dose may later be increased to 100 mg losartan (40 ml of COZAAR suspension) once daily. 
Pri nekaterih bolnikih se odmerek kasneje lahko poveča na 100 mg losartana (40 ml COZAAR suspenzije) enkrat na dan.
MSD Chibropharm GmbH Postfach 1202 D-85530 Haar, Germany 
Nemčija MSD Chibropharm GmbH Postfach 1202 D-85530
These conditions should be corrected prior to administration of losartan, or a lower starting dose should be used (see section 4.2). 
Pred začetkom zdravljenja z losartanom je treba ta stanja pozdraviti ali pa uporabiti manjši začetni odmerek (glejte poglavje 4.2).
For Healthcare providers only: See Package Leaflet for instructions on how to prepare Losartan potassium oral suspension. 
Samo za zdravstveno osebje: za navodila, kako pripraviti peroralno suspenzijo kalijevega losartanata, glejte Navodilo za uporabo.
Losartan should be used with caution in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. 
Losartan je treba pri bolnikih z obojestranskim zoženjem ledvične arterije ali zoženjem arterije ene same delujoče ledvice previdno uporabljati.
This applies particularly when losartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function. 
To velja še posebej takrat, ko se losartan daje ob prisotnosti drugih stanj, ki lahko okvarijo ledvice (zvišana telesna temperatura, dehidracija).
Merck Sharp & Dohme Bulgaria EOOD 
Bolgarija Merck Sharp & Dohme Bulgaria EOOD
Because of the potential for adverse effects on the nursing infant, losartan is contraindicated during breast-feeding (see section 4.3). 
Zaradi možnih neželenih učinkov na dojenčka je losartan v času dojenja kontraindiciran (glejte poglavje 4.3).
The difference in blood pressure increase as compared to placebo was largest in the middle dose group (6.70 mm Hg middle dose vs. 
Razlika v povečanju krvnega tlaka v času, ko je učinek zdravila najmanjši, v primerjavi s placebom je bila večja v skupini s srednjim odmerkom (6,70 mmHg srednji odmerek, 5,38 mmHg večji odmerek).
For more information, talk to your doctor. 
Za več informacij prosite zdravnika.
The suspension should be stored in a refrigerator at 2-8ºC for up to 4 weeks. 
Suspenzijo shranjujte v hladilniku pri 2-8 ºC do 4 tedne.
Losartan may be administered with other antihypertensive agents, especially with diuretics (e.g. hydrochlorothiazide). 
Losartan se lahko jemlje skupaj z drugimi antihipertenzivnimi zdravili, še posebej z diuretiki (npr. hidroklorotiazidom).
Investigations: common: hypoglycaemia, hyperkalaemia 
Preiskave: pogoste: hipoglikemija, hiperkaliemija
In a clinical study conducted in type 2 diabetic patients with nephropathy, the incidence of hyperkalemia was higher in the group treated with losartan as compared to the placebo group (see section 4.8). 
V klinični študiji pri bolnikih s sladkorno boleznijo tipa 2 in nefropatijo je bila pojavnost hiperkaliemije večja v skupini, ki je prejemala losartan, kot v skupini, ki je prejemala placebo (glejte poglavje 4.8).
-It is not recommended in children with glomerular filtration rate < 30 ml/ min / 1.73 m2, as no data are available (see also section 4.4). 
- Losartana ne priporočamo za uporabo pri otrocih, ki imajo hitrost glomerulne filtracije < 30 ml/min/1,73 m2, ker ni na voljo nobenih podatkov (glejte tudi poglavje 4.4).
LABORATÓRIO MEDINFAR, Produtos Farmacêuticos, SA Rua Manuel Ribeiro de Pavia, 1-1° Venda Nova 
Portugalska LABORATÓRIO MEDINFAR, Produtos Farmacêuticos, SA Rua Manuel Ribeiro de Pavia, 1-1°
Special caution is necessary when you are treated with a ßblocker concomitantly, 
Posebna previdnost je potrebna, če sočasno jemljete beta zaviralec.
In a clinical study conducted in type 2 diabetic patients with nephropathy, 9.9 % of patients treated with Losartan tablets developed hyperkalaemia >5.5 mEq/l and 3.4 % of patients treated with placebo Post-marketing experience 
V klinični študiji, ki so jo izvedli pri bolnikih s sladkorno boleznijo tipa 2 in nefropatijo, se je hiperkaliemija > 5,5 mEq/l pojavila pri 9,9 % bolnikov, zdravljenih z losartanom, ter 3,4 % bolnikov, ki so prejemali placebo.
COZAAR powder is a white to off-white powder. 
COZAAR prašek je bel do sivo-bel prašek.
• a 473 ml white, high-density polyethylene (HDPE) bottle of solvent, 
• 473 ml vehikla v beli HDPE plastenki (high-density polyethylene - polietilen visoke gostote)
• if your liver function is severely impaired, 
• če imate hudo okvaro jeter,
Merck Sharp & Dohme OÜ Peterburi tee 46 
Estonija Merck Sharp & Dohme OÜ Peterburi tee 46
The following side effects have been reported with COZAAR: 
Poročali so o naslednjih neželenih učinkih zdravila COZAAR:
HOW TO TAKE COZAAR 
KAKO JEMATI ZDRAVILO COZAAR
Losartan is not recommended in children with glomerular filtration rate < 30 ml/ min/1.73 m2as no data are available (see section 4.2). 
Losartana ne priporočamo za uporabo pri otrocih, ki imajo hitrost glomerulne filtracije < 30 ml/min/1,73 m2, ker ni na voljo nobenih podatkov (glejte poglavje 4.2).
ANNEX II SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 
DODATEK IIPOVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJE IN NAVODILO ZA UPORABO
It was found that concomitant treatment of losartan with rifampicine (inducer of metabolism enzymes) gave a 40 % reduction in plasma concentration of the active metabolite. 
Ugotovili so, da je pri sočasnem zdravljenju z losartanom in rifampicinom (induktor presnovnih encimov) plazemska koncentracija aktivnega presnovka manjša za 40 %.
Losartan therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3 ). 
Znano je, da izpostavljenost losartanu v drugem in tretjem trimesečju nosečnosti lahko povzroči fetotoksične učinke pri človeku (zmanjšano delovanje ledvic, oligohidramnija, zapoznela zakostenitev lobanje) in toksične učinke pri novorojenčku (odpoved ledvic, hipotenzija, hiperkaliemija) (glejte tudi poglavje 5.3).
WHAT COZAAR IS AND WHAT IT IS USED FOR Losartan (COZAAR) belongs to a group of medicines known as angiotensin-II receptor antagonists. 
Losartan (COZAAR) spada v skupino zdravil, imenovanih antagonisti receptorjev angiotenzina II.